Showing results (111-120 of 369) with videos related to
Sort By:
Pageof 37
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2016
The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer PopulationGlenn Heller, Karim Fizazi, Robert McCormack, et al.Clinical Genitourinary Cancer|March 13, 2022
Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate CancerAseem Anand, Glenn Heller, Joseph Fox, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Rapid androgen cycling as treatment for patients with prostate cancerDavid Feltquate, Luke Nordquist, Caitlin Eicher, et al.Urology|May 29, 2002
Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancerMichael J Morris, Timothy Akhurst, Iman Osman, et al.European Urology Focus|February 27, 2026
ARAMON, a phase 2 open-label trial of darolutamide monotherapy in patients with biochemical recurrence or oligometastatic castration-sensitive prostate cancer after radical prostatectomy or primary radiotherapyAndrew L Laccetti, Matthew R Smith, Howard I Scher, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2016
Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate CancerMichael J Morris, Dana E Rathkopf, William Novotny, et al.Cancer|February 8, 2017
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxelAndrew J Armstrong, Fred Saad, De Phung, et al.BJU International|July 24, 2009
Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic diseaseMichael J Donovan, Iman Osman, Faisal M Khan, et al.JAMA Oncology|September 27, 2019
Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical TrialAmylou C Dueck, Howard I Scher, Antonia V Bennett, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2005
Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancerMichael J Zelefsky, Leah Ben-Porat, Howard I Scher, et al.Pageof 37